Real-World Clinical Study for Malignant Tumor-Induced Cachexia

Launched by CHANGCHUN GENESCIENCE PHARMACEUTICAL CO., LTD. · Jun 4, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a condition called malignant tumor cachexia, which is a serious weight loss and muscle wasting that can happen in people with certain types of cancer. The study aims to understand how this condition affects patients and what treatment outcomes can be expected. It involves two groups: one group includes patients who already have cachexia before the study starts, and data about their health will be collected from their medical records. The other group includes patients who develop cachexia after the study begins, and their health information will be gathered as they go through diagnosis and treatment.

To participate in this study, you need to be at least 18 years old and have a confirmed diagnosis of a malignant tumor (which means cancer). You also need to meet specific criteria for cachexia and have a life expectancy of at least two months if you are in the second group. If you join, you can expect to provide consent to participate, and your health information will be monitored over time. This study is actively recruiting participants, and they welcome individuals of all genders.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged 18 years or older (including 18 years).
• • Malignant tumor confirmed by histology or cytology (both malignant solid tumors and malignant hematologic tumors are eligible for enrollment).
• • Meeting the Fearon diagnostic criteria for cachexia.
• • Life expectancy of ≥2 months (for the prospective cohort only).
• • Able to sign the informed consent form (waiver of informed consent for the retrospective cohort).
• Exclusion Criteria:
• Retrospective Cohort:
• • Missing gender information.
• • Missing date of birth or age information.
• • Lack of any treatment or follow-up information after the date of meeting the diagnostic criteria for cachexia.
• • Prospective Cohort: (Patients with any of the following are not eligible for enrollment in this study)
• • Patients who are unable to receive any treatment for any reason.
• • Patients who cannot undergo at least one follow-up.
• • Patients whom the investigator deems unsuitable for participation in this study.